|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New Jersey Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New JerseyLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Bellerophon Therapeutics, Inc.
| | | Phone: | (908) 574-4770 | Year Established: | 2009 | Ticker: | BLPH | Exchange: | NASDAQ | Main Contact: | Jonathan Peacock, Chairman | | Other Contacts: | Amy Edmonds, VP, Clinical Operations & Administration Martin Dekker, VP, Device Engineering Parag Shah, Ph.D., VP, Project Management & Distribution Peter Fernandes, Chief Regulatory and Safety Officer Deborah A. Quinn, M.D., CMO Fabian Tenenbaum, CEO
| | Company Description | Bellerophon is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development. | |
|
|
|
|
|